Management of heart failure with reduced ejection fraction after ESC 2016 heart failure guidelines: the Linx Registry

Aims: In May 2016, a new version of the European Society of Cardiology (ESC) Guidelines for the management of heart failure (HF) was released. The aim of this study was to describe the management of HF with reduced ejection fraction after the publication of ESC Guidelines. Methods and results: The L...

Descripción completa

Detalles Bibliográficos
Autores: de Frutos, Fernando, Mirabet, Sonia, Ortega-Paz, Luis, Buera, Irene, Darnés, Sara, Farré López, Núria, Pérez, Bernardo, Adeliño, Raquel, Bascompte, Ramón, Pérez-Rodón, Jordi, Aparicio, Xavier, Sutil-Vega, Mario, Soto, Adriana, Faraudo, Mercedes, Cainzos-Achirica, Miguel, Manito Lorite, Nicolás
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/44862
Acceso en línea:http://hdl.handle.net/10230/44862
http://dx.doi.org/10.1002/ehf2.12567
Access Level:acceso abierto
Palabra clave:Chronic heart failure
Guidelines
Heart failure
Management
Sacubitril/valsartan
id ES_09d6eff218ee8e39f38da2a6a5060cfd
oai_identifier_str oai:recercat.cat:10230/44862
network_acronym_str ES
network_name_str España
repository_id_str
spelling Management of heart failure with reduced ejection fraction after ESC 2016 heart failure guidelines: the Linx Registryde Frutos, FernandoMirabet, SoniaOrtega-Paz, LuisBuera, IreneDarnés, SaraFarré López, NúriaPérez, BernardoAdeliño, RaquelBascompte, RamónPérez-Rodón, JordiAparicio, XavierSutil-Vega, MarioSoto, AdrianaFaraudo, MercedesCainzos-Achirica, MiguelManito Lorite, NicolásChronic heart failureGuidelinesHeart failureManagementSacubitril/valsartanAims: In May 2016, a new version of the European Society of Cardiology (ESC) Guidelines for the management of heart failure (HF) was released. The aim of this study was to describe the management of HF with reduced ejection fraction after the publication of ESC Guidelines. Methods and results: The Linx registry is a multicentre, observational, cross-sectional study from 14 Catalan hospitals that enrolled 1056 patients with HF and reduced left ventricular ejection fraction (≤40%) from 1 February to 30 April 2017 in outpatient cardiology clinics. Results were compared between hospitals according to their level of complexity in our own registry and compared with previously published registries similar to ours. Sacubitril/valsartan was prescribed to 23.9% of patients in our population, as a consequence, use of angiotensin-converting enzyme inhibitor and angiotensin receptor blockers in monotherapy decreased to 48.1% and 16.9%, respectively, and prescription of beta-blockers (91.8%), mineralocorticoid receptor antagonists (72.7%), and ivabradine (21.4%) remained similar to previous registries. Target doses of beta-blockers (25.4%), angiotensin-converting enzyme inhibitors (24.9%), angiotensin receptor blockers (7.7%), sacubitril/valsartan (8.1%), and mineralocorticoid receptor antagonists (19.7%) were accomplished in a low proportion of patients. Our results also suggest that prescription and up-titration of class I HF drugs were greater in hospitals with higher level of complexity. Conclusions: The Linx registry shows an appropriate adherence to pharmacological recommendations from ESC HF Guidelines despite a low proportion of patients reached target doses. Almost one-quarter of patients were under treatment with sacubitril/valsartan a few months after ESC HF Guidelines recommendations.Wiley202020202020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/44862http://dx.doi.org/10.1002/ehf2.12567reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésCopyright © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.http://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/448622026-05-29T05:05:01Z
dc.title.none.fl_str_mv Management of heart failure with reduced ejection fraction after ESC 2016 heart failure guidelines: the Linx Registry
title Management of heart failure with reduced ejection fraction after ESC 2016 heart failure guidelines: the Linx Registry
spellingShingle Management of heart failure with reduced ejection fraction after ESC 2016 heart failure guidelines: the Linx Registry
de Frutos, Fernando
Chronic heart failure
Guidelines
Heart failure
Management
Sacubitril/valsartan
title_short Management of heart failure with reduced ejection fraction after ESC 2016 heart failure guidelines: the Linx Registry
title_full Management of heart failure with reduced ejection fraction after ESC 2016 heart failure guidelines: the Linx Registry
title_fullStr Management of heart failure with reduced ejection fraction after ESC 2016 heart failure guidelines: the Linx Registry
title_full_unstemmed Management of heart failure with reduced ejection fraction after ESC 2016 heart failure guidelines: the Linx Registry
title_sort Management of heart failure with reduced ejection fraction after ESC 2016 heart failure guidelines: the Linx Registry
dc.creator.none.fl_str_mv de Frutos, Fernando
Mirabet, Sonia
Ortega-Paz, Luis
Buera, Irene
Darnés, Sara
Farré López, Núria
Pérez, Bernardo
Adeliño, Raquel
Bascompte, Ramón
Pérez-Rodón, Jordi
Aparicio, Xavier
Sutil-Vega, Mario
Soto, Adriana
Faraudo, Mercedes
Cainzos-Achirica, Miguel
Manito Lorite, Nicolás
author de Frutos, Fernando
author_facet de Frutos, Fernando
Mirabet, Sonia
Ortega-Paz, Luis
Buera, Irene
Darnés, Sara
Farré López, Núria
Pérez, Bernardo
Adeliño, Raquel
Bascompte, Ramón
Pérez-Rodón, Jordi
Aparicio, Xavier
Sutil-Vega, Mario
Soto, Adriana
Faraudo, Mercedes
Cainzos-Achirica, Miguel
Manito Lorite, Nicolás
author_role author
author2 Mirabet, Sonia
Ortega-Paz, Luis
Buera, Irene
Darnés, Sara
Farré López, Núria
Pérez, Bernardo
Adeliño, Raquel
Bascompte, Ramón
Pérez-Rodón, Jordi
Aparicio, Xavier
Sutil-Vega, Mario
Soto, Adriana
Faraudo, Mercedes
Cainzos-Achirica, Miguel
Manito Lorite, Nicolás
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Chronic heart failure
Guidelines
Heart failure
Management
Sacubitril/valsartan
topic Chronic heart failure
Guidelines
Heart failure
Management
Sacubitril/valsartan
description Aims: In May 2016, a new version of the European Society of Cardiology (ESC) Guidelines for the management of heart failure (HF) was released. The aim of this study was to describe the management of HF with reduced ejection fraction after the publication of ESC Guidelines. Methods and results: The Linx registry is a multicentre, observational, cross-sectional study from 14 Catalan hospitals that enrolled 1056 patients with HF and reduced left ventricular ejection fraction (≤40%) from 1 February to 30 April 2017 in outpatient cardiology clinics. Results were compared between hospitals according to their level of complexity in our own registry and compared with previously published registries similar to ours. Sacubitril/valsartan was prescribed to 23.9% of patients in our population, as a consequence, use of angiotensin-converting enzyme inhibitor and angiotensin receptor blockers in monotherapy decreased to 48.1% and 16.9%, respectively, and prescription of beta-blockers (91.8%), mineralocorticoid receptor antagonists (72.7%), and ivabradine (21.4%) remained similar to previous registries. Target doses of beta-blockers (25.4%), angiotensin-converting enzyme inhibitors (24.9%), angiotensin receptor blockers (7.7%), sacubitril/valsartan (8.1%), and mineralocorticoid receptor antagonists (19.7%) were accomplished in a low proportion of patients. Our results also suggest that prescription and up-titration of class I HF drugs were greater in hospitals with higher level of complexity. Conclusions: The Linx registry shows an appropriate adherence to pharmacological recommendations from ESC HF Guidelines despite a low proportion of patients reached target doses. Almost one-quarter of patients were under treatment with sacubitril/valsartan a few months after ESC HF Guidelines recommendations.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/44862
http://dx.doi.org/10.1002/ehf2.12567
url http://hdl.handle.net/10230/44862
http://dx.doi.org/10.1002/ehf2.12567
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403129190023168
score 15,811543

Similares en LA Referencia